Literature DB >> 4008928

Augmentation of NK cell activity in tissue specific sites by liposomes incorporating MTP-PE.

J E Talmadge, M Schneider, M Collins, H Phillips, R B Herberman, R H Wiltrout.   

Abstract

Liposomes incorporating a variety of immunomodulators have been shown to activate macrophages and monocytes for tumoricidal activity both in vivo and in vitro. We report that in addition to the activation of macrophages, the i.v. injection of liposomes (multilamellar vesicles) that have encapsulated muramyl tripeptide-phosphatidylethanolamine (MTP-PE) could also augment interstitial natural killer (NK) cell activity in the lung and the liver. In contrast, liposomes incorporating MTP-PE were unable to augment NK cell activity in the spleen, peripheral blood, or peritoneal cavity (after i.p. injection). In addition, liposomes did not augment splenic NK cell activity in vitro. This suggests that the augmentation of NK cell activity in the lungs and liver was not due to direct effects of the liposomes but may have been a secondary effect mediated by a monokine. The augmentation of pulmonary NK cell activity was paralleled by the nonspecific immunoprophylaxis of experimental pulmonary metastases. The augmented NK cell activity, as well as the enhanced nonspecific immunoprophylactic activity, was reduced by pretreatment of the mice with anti-asialo GM1 antiserum. Thus, the augmentation of organ-associated NK cell activity by liposomes incorporating MTP/PE plays a major role in the host's increased resistance to the formation of experimental metastases.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4008928

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

Review 1.  Mifamurtide: a review of its use in the treatment of osteosarcoma.

Authors:  James E Frampton
Journal:  Paediatr Drugs       Date:  2010-06       Impact factor: 3.022

2.  Comparison of immunomodulatory and immunotherapeutic properties of biologic response modifiers.

Authors:  J E Talmadge; M A Chirigos
Journal:  Springer Semin Immunopathol       Date:  1985

Review 3.  Mifamurtide for the treatment of nonmetastatic osteosarcoma.

Authors:  Kosei Ando; Kanji Mori; Nedège Corradini; Françoise Redini; Dominique Heymann
Journal:  Expert Opin Pharmacother       Date:  2011-02       Impact factor: 3.889

4.  Antitumor reactivity induced by liposomal MTP-PE in a liver metastasis model of colon cancer in the rat.

Authors:  K Thomas; A M Nijenhuis; B H Dontje; T Daemen; G L Scherphof
Journal:  Clin Exp Metastasis       Date:  1995-09       Impact factor: 5.150

5.  Modulation of natural killer cytotoxicity by muramyl dipeptide and trehalose dimycolate incorporated in squalane droplets.

Authors:  K N Masihi; W Lange; B Rohde-Schulz
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

6.  Inhibition of spontaneous pulmonary metastases of Lewis lung carcinoma by oral treatment with Respivax and Broncho-Vaxom.

Authors:  K T Kassabov; J N Stoychkov
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

Review 7.  Natural Killer Cell Immunotherapy for Osteosarcoma.

Authors:  Brian P Tullius; Buhvana A Setty; Dean A Lee
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

8.  Therapy of human ovarian cancer xenografts with intraperitoneal liposome encapsulated muramyl-tripeptide phosphoethanolamine (MTP-PE) and recombinant GM-CSF.

Authors:  S T Malik; D Martin; I Hart; F Balkwill
Journal:  Br J Cancer       Date:  1991-03       Impact factor: 7.640

9.  Muramyl peptides confer hepatoprotection against murine viral hepatitis.

Authors:  K N Masihi; H Kröger; W Lange; L Chedid
Journal:  Int J Immunopharmacol       Date:  1989
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.